These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 20980796

  • 1. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
    MacIntyre CR, Egerton T, McCaughey M, Parrino J, Campbell BV, Su SC, Pagnoni MF, Stek JE, Xu J, Annunziato PW, Chan IS, Silber JL.
    Hum Vaccin; 2010 Nov; 6(11):894-902. PubMed ID: 20980796
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.
    J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS, Silber JL.
    Vaccine; 2010 Jun 07; 28(25):4204-9. PubMed ID: 20416263
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
    Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, Schuind A, Li P, Jain VK, Innis BL.
    Vaccine; 2017 Nov 01; 35(46):6321-6328. PubMed ID: 28987445
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older.
    Sutradhar SC, Wang WW, Schlienger K, Stek JE, Xu J, Chan IS, Silber JL.
    Clin Vaccine Immunol; 2009 May 01; 16(5):646-52. PubMed ID: 19261769
    [Abstract] [Full Text] [Related]

  • 11. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
    Diez-Domingo J, Weinke T, Garcia de Lomas J, Meyer CU, Bertrand I, Eymin C, Thomas S, Sadorge C.
    Vaccine; 2015 Feb 04; 33(6):789-95. PubMed ID: 25555381
    [Abstract] [Full Text] [Related]

  • 12. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.
    Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J.
    Clin Infect Dis; 2012 Apr 04; 54(7):922-8. PubMed ID: 22291101
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.
    Benson CA, Andersen JW, Macatangay BJC, Mailliard RB, Rinaldo CR, Read S, Bozzolo DR, Purdue L, Jennings C, Keefer MC, Glesby M, Tebas P, Russell AF, Martin J, Annunziato P, Popmihajlov Z, Lennox JL.
    Clin Infect Dis; 2018 Nov 13; 67(11):1712-1719. PubMed ID: 29590326
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
    Blatter MM, Klein NP, Shepard JS, Leonardi M, Shapiro S, Schear M, Mufson MA, Martin JM, Varman M, Grogg S, London A, Cambron P, Douha M, Nicholson O, da Costa C, Innis BL.
    Pediatr Infect Dis J; 2012 Aug 13; 31(8):e133-40. PubMed ID: 22622699
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.
    Choi WS, Choi JH, Choi JY, Eom JS, Kim SI, Pai H, Peck KR, Sohn JW, Cheong HJ.
    J Korean Med Sci; 2016 Jan 13; 31(1):13-7. PubMed ID: 26770032
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.
    Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, Meechan C, Li D, Schlienger K, Chan I, Sadoff J, Schödel F, Silber JL.
    Vaccine; 2007 Mar 01; 25(11):2139-44. PubMed ID: 17250932
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.